// App-Quantinova.ai

DDRE-07 : DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL INHIBITION

Researchers

Presenter

  • Elisa Izquierdo

Principal Investigators

  • Diana Carvalho

  • Alan Mackay

  • Sara Temelso

  • Jessica K R Boult

  • Valeria Molinari

  • Mark Stubbs

  • Yura Grabovska

  • Lu Yu

  • Jyoti Choudhary

  • Sarita Depani

  • Patricia oHare

  • Simon P Robinson

  • Michael Hubank

  • Darren Hargrave

  • Chris Jones

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Great Ormond Street Hospital, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse intrinsic pontine glioma

Biomarkers

  • Mitogen-activated protein kinase

  • Dual specificity mitogen-activated protein kinase kinase 1

  • Phosphatidylinositol 3-kinase regulatory subunit alpha

  • Extracellular signal-regulated kinase

  • Neurofibromatosis type 1

Drug/Treatment

  • Ulixertinib

  • Trametinib

  • dasatinib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved